Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACVRL1 | P37023 | 7/20 | 0.61 |
| ▸ | MERTK | Q12866 | 2/20 | 0.57 |
| ▸ | KDR | P35968 | 7/20 | 0.49 |
| ▸ | KIT | P10721 | 6/20 | 0.49 |
| ▸ | TEK | Q02763 | 1/20 | 0.49 |
| ▸ | FLT3 | P36888 | 8/20 | 0.47 |
| ▸ | PLK4 | O00444 | 2/20 | 0.42 |
| ▸ | AURKA | O14965 | 2/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.42 |
| ▸ | ABL1 | P00519 | 2/20 | 0.42 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.42 |
| ▸ | INSR | P06213 | 2/20 | 0.42 |
| ▸ | LCK | P06239 | 2/20 | 0.42 |
| ▸ | CSF1R | P07333 | 2/20 | 0.42 |
| ▸ | LYN | P07948 | 2/20 | 0.42 |
| ▸ | MET | P08581 | 2/20 | 0.42 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.42 |
| ▸ | SRC | P12931 | 2/20 | 0.42 |
| ▸ | FLT1 | P17948 | 2/20 | 0.42 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL58436 | 0.91 | ACVRL1 (0.59) | ACVRL1MERTKKDRKITTEK | |
| SCHEMBL65127 | 0.91 | ACVRL1 (0.65) | ACVRL1MERTKKDRKITTEK | |
| SCHEMBL58166 | 0.91 | ACVRL1 (0.61) | ACVRL1MERTKKDRKITTEK | |
| SCHEMBL58253 | 0.90 | ACVRL1 (0.58) | ACVRL1MERTKKDRKITTEK | |
| SCHEMBL65790 | 0.89 | ACVRL1 (0.63) | ACVRL1MERTKKDRKITTEK | |
| SCHEMBL58292 | 0.89 | ACVRL1 (0.58) | ACVRL1MERTKKDRKITTEK | |
| Hydrochloric Acid SCHEMBL58421 | 0.88 | ACVRL1 (0.62) | ACVRL1MERTKKDRKITTEK | |
| SCHEMBL59916 | 0.88 | ACVRL1 (0.66) | ACVRL1MERTKKDRKITTEK | |
| SCHEMBL59783 | 0.87 | ACVRL1 (0.66) | ACVRL1MERTKKDRKITTEK | |
| SCHEMBL60419 | 0.87 | ACVRL1 (0.62) | ACVRL1MERTKKDRKITTEK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101466710-B | Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER HEALTHCARE LLC | 2013-05-29 | — | — | CN | claimed |
| EP-1957485-B1 | SUBSTITUTED 4-AMINO-PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER HEALTHCARE LLC (US) | 2013-02-13 | — | — | EP | claimed |
| US-8143393-B2 | Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER HEALTHCARE LLC (US) | 2012-03-27 | — | — | US | claimed |
| US-20100179125-A1 | SUBSTITUTED 4-AMINO-PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER HEALTHCARE LLC (US) | 2010-07-15 | — | — | US | claimed |
| US-20100063038-A1 | Substituted 4-Amino-Pyrrolotriazine Derivatives Useful for Treating Hyper-Proliferative Disorders and Diseases Associated with Angiogenesis | BAYER HEALTHCARE LLC | 2010-03-11 | — | — | US | claimed |
| CN-101466710-A | Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER HEALTHCARE LLC (US) | 2009-06-24 | — | — | CN | claimed |
| EP-1575591-A4 | HETEROCYCLES AND USES THEREOF | ARIAD PHARMA INC (US) | 2007-09-12 | — | — | EP | claimed |
| US-7238679-B2 | Heterocycles and uses thereof | ARIAD PHARMACEUTICALS, INC. (US) | 2007-07-03 | — | — | US | claimed |
| EP-1575591-A1 | HETEROCYCLES AND USES THEREOF | ARIAD PHARMACEUTICALS, INC. (US) | 2005-09-21 | — | — | EP | claimed |
| US-20040171586-A1 | Heterocycles and uses thereof | ARIAD PHARMACEUTICALS, INC. | 2004-09-02 | — | — | US | claimed |
| WO-2004058267-A1 | HETEROCYCLES AND USES THEREOF | ARIAD PHARMACEUTICALS, INC. (US) | 2004-07-15 | — | — | WO | claimed |
| US-20040048881-A1 | Quinazoline derivatives with anti-tumour activity | ASTRAZENECA AB (SE) | 2004-03-11 | — | — | US | claimed |
| US-20040044015-A1 | Quinazoline derivatives | ASTRAZENECA AB (SE) | 2004-03-04 | — | — | US | claimed |
| CN-101466710-B | Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER HEALTHCARE LLC | 2013-05-29 | — | — | CN | disclosed |
| EP-1957485-B1 | SUBSTITUTED 4-AMINO-PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER HEALTHCARE LLC (US) | 2013-02-13 | — | — | EP | disclosed |
| EP-1957485-B1 | SUBSTITUTED 4-AMINO-PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER HEALTHCARE LLC (US) | 2013-02-13 | — | — | EP | disclosed |
| US-6939866-B2 | Quinazoline derivatives | ASTRAZENECA AB (SE) | 2005-09-06 | — | — | US | disclosed |
| US-20040171586-A1 | Heterocycles and uses thereof | ARIAD PHARMACEUTICALS, INC. | 2004-09-02 | — | — | US | disclosed |
| WO-2004058267-A1 | HETEROCYCLES AND USES THEREOF | ARIAD PHARMACEUTICALS, INC. (US) | 2004-07-15 | — | — | WO | disclosed |
| US-20040044015-A1 | Quinazoline derivatives | ASTRAZENECA AB (SE) | 2004-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044015-A1 | Quinazoline derivatives | NQO2, NRAS, TOP1 | ACVRL1 4199/4885MERTK 3842/4885KDR 2216/4885 |
| US-20040048881-A1 | Quinazoline derivatives with anti-tumour activity | TOP1, NQO2, ABCC1 | ACVRL1 4103/4885MERTK 3932/4885KDR 2192/4885 |
| US-20100179125-A1 | SUBSTITUTED 4-AMINO-PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | CDK4, CDKL4, MKI67 | ACVRL1 941/4885MERTK 1749/4885KDR 41/4885 |
| US-20100063038-A1 | Substituted 4-Amino-Pyrrolotriazine Derivatives Useful for Treating Hyper-Proliferative Disorders and Diseases Associated with Angiogenesis | CDK4, CDKL4, MKI67 | ACVRL1 963/4885MERTK 1905/4885KDR 41/4885 |
| US-20040171586-A1 | Heterocycles and uses thereof | CBR1, CBR3, RCOR1 | ACVRL1 1551/4885MERTK 3681/4885KDR 2329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.